Brinker Capital’s Puma Biotechnology PBYI Stock Holding History

Brinker Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,790	Closed	-$214K	–	999
2017 Q3	$214K	Buy	+1,790	New	+$166K	0.01%	900

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brinker Capital's PBYI Position: Q4 2017 in Review

Brinker Capital sold out of Puma Biotechnology (PBYI) in Q4 2017, closing a stake of 1,790 shares — an estimated $214K sold.

Brinker Capital first reported a position in PBYI in Q3 2017 and held it in 1 quarter. The position peaked at $214K in Q3 2017. 203 funds tracked by Wall St. Rank hold PBYI as of Q4 2017.

Brinker Capital reported no remaining Puma Biotechnology position as of Q4 2017 after selling out during the quarter.
Brinker Capital sold 1,790 Puma Biotechnology shares in Q4 2017, an estimated $214K.
Brinker Capital first reported a position in Puma Biotechnology in Q3 2017 and held it in 1 quarter.
Brinker Capital's Puma Biotechnology position peaked at $214K in Q3 2017.
203 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2017.

Based on Brinker Capital's 13F filing for Q4 2017, filed 14 Feb 2018.